These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21684381)

  • 21. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?
    Sultana F; Winch K; Saville M; Brotherton JML
    Int J Cancer; 2019 Jun; 144(12):2964-2971. PubMed ID: 30536935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).
    Young EJ; Tabrizi SN; Brotherton JM; Wark JD; Pyman J; Saville M; Wrede CD; Jayasinghe Y; Tan J; Gertig DM; Pitts M; Garland SM
    BMC Cancer; 2013 Jun; 13():296. PubMed ID: 23777549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Declines in Human Papillomavirus (HPV)-Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008-2015.
    Niccolai LM; Meek JI; Brackney M; Hadler JL; Sosa LE; Weinberger DM
    Clin Infect Dis; 2017 Sep; 65(6):884-889. PubMed ID: 28520854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.
    Budd AC; Sturrock CJ
    Sex Health; 2010 Sep; 7(3):328-34. PubMed ID: 20719223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Kann H; Hortlund M; Eklund C; Dillner J; Faust H
    Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
    Pérez-Castro S; Lorenzo-Mahía Y; Iñarrea Fernández A; Lamas-González MJ; Sarán-Díez MT; Rubio-Alarcón J; Reboredo-Reboredo MC; Mosteiro-Lobato S; López-Miragaya I; Torres-Piñón J; Melón-García S
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):479-85. PubMed ID: 24274937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
    Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
    J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program.
    Baldur-Felskov B; Dehlendorff C; Junge J; Munk C; Kjaer SK
    Cancer Causes Control; 2014 Jul; 25(7):915-22. PubMed ID: 24797870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
    Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
    Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
    Palmer T; Wallace L; Pollock KG; Cuschieri K; Robertson C; Kavanagh K; Cruickshank M
    BMJ; 2019 Apr; 365():l1161. PubMed ID: 30944092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
    Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M
    Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
    Simonella LM; Lewis H; Smith M; Neal H; Bromhead C; Canfell K
    BMC Infect Dis; 2013 Mar; 13():114. PubMed ID: 23452957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study.
    Rodriguez AM; Zeybek B; Vaughn M; Westra J; Kaul S; Montealegre JR; Lin YL; Kuo YF
    Cancer; 2020 Apr; 126(8):1656-1667. PubMed ID: 32037524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
    Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.